Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 6M | 7M | 6M | 2M | 3M |
| Gross Profit | 3M | -2M | -420K | 1M | 3M |
| Operating Income | -34M | -42M | -46M | -35M | -26M |
| EBITDA | -26M | -34M | -39M | -35M | -25M |
| Net Income | -33M | -45M | -43M | -35M | -26M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0011
+0.00% today
1Y Change
-72.25%
Window
Jun 23, 2025 → Jun 11, 2026
Coverage: 224 bars · Jun 23, 2025 → Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Scorpius Holdings, Inc. (SCPX) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 72.2% across the available one-year price window (Jun 23, 2025 → Jun 11, 2026). Baseline metrics include revenue growth of -10.7%, EPS growth of +96.2%, a dividend yield of 0.0%. What stands out right now is revenue -10.7%, EPS +96.2%, free cash flow +19.8% with operating margin -2538.2% and ROIC -48791205.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SCPX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SCPX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SCPX Max Drawdown
-99.80%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SCPX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.9M
+39.5% YoY
FY Net Income
-$26.0M
+25.7% YoY
Free Cash Flow
-$22.4M
+44.1% YoY
Revenue Growth
-10.7%
EPS Growth
+96.2%
Gross Margin
6.1%
Net Margin
-1793.3%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 6M | 7M | 6M | 2M | 3M |
| Gross Profit | 3M | -2M | -420K | 1M | 3M |
| Operating Income | -34M | -42M | -46M | -35M | -26M |
| EBITDA | -26M | -34M | -39M | -35M | -25M |
| Net Income | -33M | -45M | -43M | -35M | -26M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1M | 185K | 3M | 8M | 11M |
| Total Assets | 39M | 51M | 104M | 121M | 124M |
| Total Liabilities | 38M | 23M | 32M | 9M | 9M |
| Shareholder Equity | 6M | 31M | 74M | 113M | 116M |
| Total Debt | 29M | 14M | 9M | 2M | 2M |
| Net Debt | 28M | 14M | 6M | -6M | -9M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
22M
+42.2% YoY
Capital Expenditures
338K
+82.3% YoY
Free Cash Flow
22M
+44.1% YoY
Key ratios
Gross Margin
6.1%
Operating Margin
-2538.2%
Net Margin
-1793.3%
ROE
427.8%
Debt / Equity
-0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.